| Date | Title | Description |
| 08.05.2025 | CVRx Reports First Quarter 2025 Financial and Operating Results | - |
| 04.02.2025 | CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results | - |
| 12.01.2025 | Vensana Capital: $425 Million Fund III Closed For Investing In Breakthrough Medical Technologies | Vensana Capital announced the closing of Vensana Capital III with $425 million in committed capital. This fund was oversubscribed at its hard cap with the support of the firm’s existing limited partners alongside select new institutional in... |
| 04.11.2024 | CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 | - |
| 29.10.2024 | CVRx Reports Third Quarter 2024 Financial and Operating Results | - |
| 12.09.2024 | CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim | - |
| 02.08.2024 | CVRx Announces Increased Inpatient Payment for Barostim Procedure | - |
| 29.07.2024 | CVRx Reports Second Quarter 2024 Financial and Operating Results | - |
| 16.07.2024 | Innovative Tech Tackles Heart Failure Symptoms | (BPT) - Heart failure affects more than six million adults in the United States, according to the Centers for Disease Control and Prevention, with numbers expected to significantly rise over the next decade. It is a condition that develops ... |
| 30.04.2024 | CVRx Reports First Quarter 2024 Financial and Operating Results | - |
| 31.01.2024 | CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer | - |
| 25.01.2024 | CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results | - |
| 04.01.2024 |
CVRx is one of the best performing stocks out of Minnesota | CVRx’s Barostim Neo [Image courtesy of CVRx]CVRx (Nasdaq:CVRX) reached near the top of a list of Minnesota S&P 500 companies with best-performing stocks.
With a 71% return in 2023, CVRx was No. 4 among the Minnesota “Fantastic Four” sto... |
| 20.04.2023 | CVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023 | MINNEAPOLIS, April 20, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. CVRX ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neurom... |
| 27.01.2023 |
CVRx nearly doubles its revenue in Q4 | CVRx (NASDAQ: CVRX) reported Street-beating Q4 results amid increased adoption of its implantable neuromodulation system for treating heart failure symptoms.
Minneapolis-based CVRx announced yesterday evening that it lost $10.5 million, or ... |
| 05.08.2021 | CVRx : Reports Second Quarter 2021 Financial and Operating Results (Form 8-K) | CVRx Reports Second Quarter 2021 Financial and Operating Results
Second Quarter 2021 Revenue of $3.1 million, a 150% Increase Over Prior Year
MINNEAPOLIS, August 4, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-s... |
| 05.07.2021 | Ysios Capital anuncia la salida a bolsa en el NASDAQ de su compañía participada CVRx | 05/07/2021
Nota de prensa
YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU COMPAÑÍA PARTICIPADA CVRX.
− CVRx, Inc. (Minneapolis, Estados Unidos) es una compañía de dispositivos médicos en fase comercial centrada en soluciones d... |
| 05.07.2021 | Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ | 05/07/2021
Press release
YSIOS CAPITAL´S PORTFOLIO COMPANY CVRX INC. PRICES IPO ON NASDAQ.
− CVRx, Inc. (Minneapolis, US) is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative an... |
| 07.07.2020 | CVRx Raises $50 Million in New Equity Financing | - |
| 07.07.2020 | CVRx raises $50m to support Barostim Neo commercialization | CVRx’s Barostim Neo [Image courtesy of CVRx]CVRx has raised $50 million in its latest round of equity financing — money the company will use to support the U.S. commercialization of its Barostim Neo heart failure treatment device.
New inves... |
| 07.07.2020 | CVRx® Raises $50 Million in New Equity Financing | MINNEAPOLIS, July 7, 2020 /PRNewswire/ -- CVRx, Inc., a private medical device company with a novel technology that treats patients suffering from chronic heart failure ("HF") and resistant hypertension, announced today that it ra... |
| 14.10.2019 | Top 10 VCs investing in medical device companies | They include NEA, Versant Ventures, SOSV and Innova Memphis
Healthtech is a big and broad space, so much so that there are whole subsectors that see more investments than entire industries.
Medical device companies, for example, raised $2.9... |
| 09.05.2019 | HRS 2019: Study shows no danger to CRM devices from airport body scans | [San Francisco image from Unsplash]Airport body scanners don’t appear to interfere with pacemakers and defibrillators, and noninvasive neurostimulation through the ear may help treat AFib. Those are but some of the insights coming out of th... |
| 15.05.2017 | AdvaMed unveils new tools to assess medical device value | AdvaMed today launched a new value initiative that includes extensive tables of questions to help medical device companies formulate value-based arguments.
The value framework also includes tools specifically designed for diagnostic technol... |
| 03.11.2016 | The top 15 healthcare deals of 2016 | There has been $13.1 billion invested across 1,287 deals so far this year
Even as venture funding has slowed down this year, healthcare has remained one of the top spaces for companies to raise money.
In the first quarter of this year, even... |
| 10.08.2016 | J&J’s venture arm backs CVRx in $93 million funding round | The lead investor was Johnson & Johnson Innovation, formerly known as Johnson & Johnson Development Corp. (JJDC), the venture capital arm of the conglomerate. Existing investors New Enterprise Associates, and Ysios BioFund I F.C.R j... |
| 10.08.2016 | Ysios Capital participa en la ronda de $113 millones de CVRx liderada por Johnson & Johnson | 10/08/2016
YSIOS CAPITAL PARTICIPA EN LA RONDA DE $113 MILLONES DE CVRX LIDERADA POR JOHNSON & JOHNSON.
La entidad de capital riesgo (venture capital) Ysios Capital, ha anunciado hoy su participación en la ampliación de capital de $11... |
| 09.08.2016 | JJDC Leads $113M Funding for CVRx | CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completing the Baroreflex Activation Therapy for... |
| 09.08.2016 | CVRx Raises $113M |
MINNEAPOLIS, MN, CVRx, a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility.
>> Click here for more funding data on CVRx
>> To export CVRx funding data to PD... |
| 09.08.2016 | NEA Joins $113M Funding for CVRx | CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completing the Baroreflex Activation Therapy for... |
| 09.08.2016 | CVRx Secures $113M in Financing | CVRx, Inc., a Minneapolis, Minnesota-based medical device company, raised $113M in financing.
The company, which has secured Series G equity financing totaling $93m and a new $20m debt facility, plans to use the proceeds for the primary pur... |
| 25.06.2016 | 5 must-read stories this week: Boeing bypasses insurers in MemorialCare deal, CVRx raises $46M | In another sign of growing frustration with rising health costs, aerospace giant Boeing Co. has agreed to contract directly for employee benefits with a major health system in Southern California, bypassing the conventional insurance model.... |
| 18.06.2016 | Maker of neuromodulator to treat heart failure, CVRx, raises $46M | “Barostim Therapy is designed to activate the Baroreflex through the afferent (sensory) pathway causing a simultaneous reduction in sympathetic activity and increase in parasympathetic activity. Restoring autonomic balance leads to a reduct... |
| 17.12.2014 | Hypertension: CVRx wins FDA nod for Barostim neo legacy | CVRx said yesterday that it won a humanitarian device exemption from the FDA for its Barostim neo legacy device, to treat drug-resistant hypertension.
The watchdog agency issues HDE approvals for devices that show promise in treating condit... |
| 15.12.2014 | CVRx’s Barostim neo gets CE Mark for use with MRIs | CVRx said its Barostim neo system was granted expanded CE Mark approval in the European Union for use with MRI procedures.
Barostim neo is used to help regulate blood flow in patients suffering from heart failure or drug-resistant hypertens... |
| 29.09.2014 | CVRx wins heart failure CE Mark for Barostim Neo neurostim device | CVRx said today that it won CE Mark approval in the European Union for its Barostim Neo device to treat heart failure patients using vagus nerve stimulation.
CVRx president & CEO Nadim Yared told MassDevice.com today that the device is ... |
| 22.09.2014 | CVRx Secures $15M Debt Facility from Silicon Valley Bank | CVRx, Inc., a Minneapolis-based medical device company, secured a $15m debt facility from Silicon Valley Bank.
The company intends to use the funds to continue to invest in the market development and clinical activities required to deliver ... |
| 28.01.2014 | Report: Medical device investing in the Midwest soared in 2013 as biotech plummeted | Buoyed by $15 million-plus rounds for Minnesota-based Conventus Orthopaedics, NxThera and CVRx, along with Cleveland-based ViewRay and ALung Technologies in Pittsburgh, the device sector saw a total of $423 million in venture dollars last y... |
| 30.10.2013 | CVRx Closes $12M Additional Financing |
MINNEAPOLIS, MN, Privately held medical device company, has closed on an additional $12 million under its Series F financing.
>> Click here for more funding data on CVRx
>> To export CVRx funding data to PDF and Excel, click... |
| 30.10.2013 | CVRx Raises Additional $12M in Series F Financing | CVRx Inc., a Minneapolis, MN-based medical device company, closed on an additional $12m in Series F financing.
Backers in the round, which brought the total amount raised by the company to date to $42m, included Ysios Capital, DaVita Health... |
| 19.07.2013 | Minnesota company raises $29.6 million for implantable hypertension technology | According to the regulatory filing, Med Dev’s officers include Brintnall, formerly of Survivalink; President and CEO Nadim Yared, formerly of Intio, Inc., VP and General Manager of Medtronic Navigation, and GE Healthcare; Founder and CTO Dr... |
| 11.07.2013 | CVRx Secures $29.6M Financing |
MINNEAPOLIS, MN, Private medical device company, has completed a private equity financing totaling $29.6 million.
>> Click here for more funding data on CVRx
>> To export CVRx funding data to PDF and Excel, click here
CVR... |
| 11.07.2013 | CVRx Completes $29.6M Equity Financing | CVRx, Inc., a Minneapolis, MN-based medical device company, has completed a $29.6m private equity financing.
The round was co-led by New Enterprise Associates and Johnson & Johnson Development Corporation with participation from existin... |
| 22.06.2010 | CVRx touts clinical trial results of blood pressure neurostim device | By Thomas Lee
CVRx Inc. of Plymouth, Minn., said Monday that hypertension patients using its Rheos stimulation device reported a sharp drop in blood pressure after four years.
In a study presented at the European Society of Hypertension mee... |
| 21.06.2010 | CVRx reports positive four-year results for its anti-blood pressure device | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 10.10.2008 | Expect to see start-ups and VCs hit standoff over valuations | When the stock market goes into the dumps, it takes a while for the effects to trickle down to start-ups. That’s because start-ups are often are working away on a project that’s isolated from the larger market — and if they’re lucky, they h... |
| 24.07.2007 | Biotech venture funding takes a hit, but devices are hot | Venture-capital financing may be at a six-year high, but the picture in life sciences is a mixed one. After a blowout first quarter, second-quarter fundings in biotechnology actually dropped 19 percent, to $1.1 billion, compared to the same... |
| - | Report: Medical device investing in the Midwest soared in 2013 as biotech plummeted | On a national scale, venture investment in medical devices suffered last year while biotech saw a jump in investments. But new data paints a different picture for healthcare companies in the Midwest.
According to data collected and analyzed... |
| - | 5 must-read stories this week: Boeing bypasses insurers in MemorialCare deal, CVRx raises $46M | Every week, we compile the most popular and thoughtful stories on MedCity News. Among this week’s highlights, Boeing has contracted directly with MemorialCare for employees in Southern California, implantable device-maker CVRx has raised a ... |
| - | Maker of neuromodulator to treat heart failure, CVRx, raises $46M | Minneapolis’ CVRx has raised $46 million from unnamed investors in support of its implantable neuromodulator to treat high blood pressure and heart failure, bringing its total equity funding to $237 million over 5 rounds, according to Crunc... |
| - | J&J’s venture arm backs CVRx in $93 million funding round | Minneapolis-based medical device maker CVRx, has raised $93 million and taken on an additional $20 million in debt to complete a clinical trial for its Barostim Neo, a proprietary implantable device that treats high blood pressure and conge... |
| - | Minnesota company raises $29.6 million for implantable hypertension technology | CVRx, a Minneapolis-based firm that has developed proprietary implantable technology for the treatment of high blood pressure and heart failure, has raised $29.6 million for advancing clinical trials of its Barostim Neo, as well as expandin... |
| - | CVRx reports positive four-year results for its anti-blood pressure device | CVRx Inc. in Plymouth, Minn. said Monday that hypertension patients using its Rheos stimulation device reported a sharp drop in blood pressure after four years.
In a study presented to the European Society of Hypertension meeting, the compa... |
